Abcam strikes antibody deal with NanoString Technologies
Cambridge-based Abcam has agreed a partnership with fellow life science tools provider NanoString Technologies, in Seattle.
The deal gives researchers using NanoString’s GeoMx Digital Spatial Profiler access to its collection of more than 6,000 recombinant monoclonal antibodies.
Abcam will manufacture and sell GeoMx-formatted antibodies through its catalog and website directly to GeoMx DSP users.
John Baker, SVP of product portfolio and innovation at Abcam, which recently moved into its new Cambridge Biomedical Campus HQ, said: "We are excited to be partnering with NanoString to support the GeoMx DSP users' ground-breaking research. Our recombinant monoclonal antibodies help ensure robust and quantitative spatial protein analysis of even the most challenging samples and may ultimately accelerate vital biomarker discoveries.”
Brad Gray, president and CEO of NanoString, said: "Researchers using our GeoMx DSP platform often want to customize their analysis. We have partnered with Abcam to facilitate access to their broad portfolio of high quality, validated antibodies to augment our off-the-shelf GeoMx protein panels. Abcam’s proven track record of antibody quality and performance was a key consideration in ensuring the success of our customer’s spatial profiling research.”
John Baker, SVP of product portfolio and innovation at Abcam, which recently moved into its new Cambridge Biomedical Campus HQ, said: "We are excited to be partnering with NanoString to support the GeoMx DSP users' ground-breaking research. Our recombinant monoclonal antibodies help ensure robust and quantitative spatial protein analysis of even the most challenging samples and may ultimately accelerate vital biomarker discoveries.”
Read more
Inside Abcam's new £46million headquarters on Cambridge Biomedical Campus
Abcam expands custom capabilities with acquisition of California-based Calico Biolabs